Summit Therapeutics (SMMT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Summit Therapeutics (SMMT) is Neutral.

The composite score behind that read is +0.13, weighing +0.26 of bullish evidence against -0.16 bearish.

Summit Therapeutics last closed at $17.59, +2.45% on the session.

Against the IVW growth benchmark the position is +1.65% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

2 graded predictions for SMMT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Summit Therapeutics in the 6th percentile on return on equity, where 100 is best.

Summit Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $13.70B.

StockMap tracks Summit Therapeutics as the 21st largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Summit Therapeutics ranks 38th of 381 in the group, against a group median of -0.08.